LIQUIDIA CORP (LQDA)
US53635D2027 - Common Stock
We assign a fundamental rating of 3 out of 10 to LQDA. LQDA was compared to 193 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of LQDA have multiple concerns. LQDA is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year LQDA has reported negative net income.
LQDA had a negative operating cash flow in the past year.
LQDA had negative earnings in each of the past 5 years.
In the past 5 years LQDA always reported negative operating cash flow.
1.2 Ratios
LQDA has a worse Return On Assets (-47.24%) than 62.30% of its industry peers.
LQDA has a worse Return On Equity (-108.10%) than 60.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.24% | ||
| ROE | -108.1% | ||
| ROIC | N/A |
ROA(3y)-45%
ROA(5y)-52.84%
ROE(3y)-88.11%
ROE(5y)-96.94%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
LQDA has a Gross Margin of 64.65%. This is in the better half of the industry: LQDA outperforms 69.63% of its industry peers.
In the last couple of years the Gross Margin of LQDA has declined.
The Profit Margin and Operating Margin are not available for LQDA so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.65% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.31%
GM growth 5Y-2.67%
2. Health
2.1 Basic Checks
LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for LQDA has been increased compared to 1 year ago.
Compared to 5 years ago, LQDA has more shares outstanding
Compared to 1 year ago, LQDA has a worse debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 0.35, we must say that LQDA is in the distress zone and has some risk of bankruptcy.
LQDA's Altman-Z score of 0.35 is in line compared to the rest of the industry. LQDA outperforms 53.93% of its industry peers.
A Debt/Equity ratio of 0.90 indicates that LQDA is somewhat dependend on debt financing.
LQDA's Debt to Equity ratio of 0.90 is on the low side compared to the rest of the industry. LQDA is outperformed by 71.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.35 |
ROIC/WACCN/A
WACC9.44%
2.3 Liquidity
A Current Ratio of 6.33 indicates that LQDA has no problem at all paying its short term obligations.
LQDA has a Current ratio of 6.33. This is in the better half of the industry: LQDA outperforms 72.77% of its industry peers.
LQDA has a Quick Ratio of 6.33. This indicates that LQDA is financially healthy and has no problem in meeting its short term obligations.
LQDA has a Quick ratio of 6.33. This is in the better half of the industry: LQDA outperforms 73.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.33 | ||
| Quick Ratio | 6.33 |
3. Growth
3.1 Past
LQDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.36%.
LQDA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.79%.
Measured over the past years, LQDA shows a very strong growth in Revenue. The Revenue has been growing by 45.20% on average per year.
EPS 1Y (TTM)-87.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y186.97%
Revenue growth 5Y45.2%
Sales Q2Q%20.94%
3.2 Future
Based on estimates for the next years, LQDA will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.96% on average per year.
The Revenue is expected to grow by 87.33% on average over the next years. This is a very strong growth
EPS Next Y-34.7%
EPS Next 2Y-13.46%
EPS Next 3Y22.43%
EPS Next 5Y19.96%
Revenue Next Year-10.16%
Revenue Next 2Y66.81%
Revenue Next 3Y118.64%
Revenue Next 5Y87.33%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
LQDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for LQDA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as LQDA's earnings are expected to grow with 22.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.46%
EPS Next 3Y22.43%
5. Dividend
5.1 Amount
No dividends for LQDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIQUIDIA CORP
NASDAQ:LQDA (12/20/2024, 8:22:51 PM)
After market: 10.5 -0.6 (-5.41%)11.1
+0.51 (+4.82%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners45.07%
Inst Owner Change14.01%
Ins Owners3.47%
Ins Owner Change0.75%
Market Cap939.50M
Analysts86.25
Price Target25.95 (133.78%)
Short Float %17.47%
Short Ratio13.28
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.59%
Min EPS beat(2)-6.02%
Max EPS beat(2)21.21%
EPS beat(4)1
Avg EPS beat(4)-31.65%
Min EPS beat(4)-75.11%
Max EPS beat(4)21.21%
EPS beat(8)2
Avg EPS beat(8)-27.28%
EPS beat(12)4
Avg EPS beat(12)-25.41%
EPS beat(16)6
Avg EPS beat(16)-19.04%
Revenue beat(2)1
Avg Revenue beat(2)-28.96%
Min Revenue beat(2)-62.04%
Max Revenue beat(2)4.12%
Revenue beat(4)1
Avg Revenue beat(4)-24.41%
Min Revenue beat(4)-62.04%
Max Revenue beat(4)4.12%
Revenue beat(8)4
Avg Revenue beat(8)-6.14%
Revenue beat(12)7
Avg Revenue beat(12)-3.92%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.44%
PT rev (3m)6.02%
EPS NQ rev (1m)-105.53%
EPS NQ rev (3m)-105.53%
EPS NY rev (1m)4.46%
EPS NY rev (3m)6.27%
Revenue NQ rev (1m)-86.51%
Revenue NQ rev (3m)-86.51%
Revenue NY rev (1m)1.22%
Revenue NY rev (3m)2.85%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 60.19 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 8.5 | ||
| P/tB | 9.09 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.63
EYN/A
EPS(NY)-1.54
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0.18
BVpS1.31
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -47.24% | ||
| ROE | -108.1% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.65% | ||
| FCFM | N/A |
ROA(3y)-45%
ROA(5y)-52.84%
ROE(3y)-88.11%
ROE(5y)-96.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.31%
GM growth 5Y-2.67%
F-Score2
Asset Turnover0.06
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.9 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 177% | ||
| Cap/Sales | 24.8% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.33 | ||
| Quick Ratio | 6.33 | ||
| Altman-Z | 0.35 |
F-Score2
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)178.83%
Cap/Depr(5y)126.49%
Cap/Sales(3y)23.04%
Cap/Sales(5y)38.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-34.7%
EPS Next 2Y-13.46%
EPS Next 3Y22.43%
EPS Next 5Y19.96%
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y186.97%
Revenue growth 5Y45.2%
Sales Q2Q%20.94%
Revenue Next Year-10.16%
Revenue Next 2Y66.81%
Revenue Next 3Y118.64%
Revenue Next 5Y87.33%
EBIT growth 1Y-108.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-93.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-191.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-180.8%
OCF growth 3YN/A
OCF growth 5YN/A